Identifying Potentially Avoidable Hospitalizations in Medicare Patients With Prostate Cancer: A Retrospective Analysis.


Journal

Journal of oncology practice
ISSN: 1935-469X
Titre abrégé: J Oncol Pract
Pays: United States
ID NLM: 101261852

Informations de publication

Date de publication:
Mar 2019
Historique:
pubmed: 12 2 2019
medline: 20 6 2020
entrez: 12 2 2019
Statut: ppublish

Résumé

If identifiable, potentially avoidable hospitalizations (PAHs) can serve as an important target for cost containment efforts in oncology. PAHs among a cohort of Medicare patients with prostate cancer were identified using a two-stage consensus-driven review process. In stage 1, two clinicians independently evaluated admissions records using a case review form, which we modified from a previous study to assess for PAHs. In stage 2, any admissions that the reviewers disagreed on or were unsure of were re-examined in a larger group of clinicians to yield a consensus determination regarding avoidability. Univariable and multivariable regression analyses were performed to identify factors predictive of PAH. There were 160 admissions among this cohort of 210 patients from January 2012 to June 2015, of which 99 were evaluable. Consensus-driven clinical review yielded an overall PAH rate of 28.3%. Factors associated with increased PAH risk were admission for symptoms related to cancer (odds ratio [OR], 7.33; P < .001), presence of a social contributor to admission (OR, 4.40; P = .014), and history of alcohol or drug abuse (OR, 4.93; P = .025). Admission for a noncancer condition was associated with decreased PAH risk (OR, 0.32; P = .011). On multivariable analysis, presence of a social contributor to admission (OR, 9.35; P = .002) and admission as a result of a noncancer condition (OR, 0.16; P = .038) remained predictive of PAH risk. A significant proportion of hospitalizations among patients with prostate cancer are potentially avoidable. Understanding factors predictive of risk for PAH can help inform programs aimed at avoiding such admissions to improve overall care quality and value.

Identifiants

pubmed: 30742550
doi: 10.1200/JOP.18.00560
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e187-e194

Auteurs

Anish B Parikh (AB)

1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

William Smith (W)

2 Icahn School of Medicine at Mount Sinai, New York, NY.

Mark Sanderson (M)

2 Icahn School of Medicine at Mount Sinai, New York, NY.

Kavita Dharmarajan (K)

2 Icahn School of Medicine at Mount Sinai, New York, NY.

Mark Liu (M)

1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Luis Isola (L)

1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Ronald D Ennis (RD)

3 Rutgers-Cancer Institute of New Jersey, New Brunswick, NJ.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH